TY - STD TI - Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106. ID - ref1 ER - TY - STD TI - Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53. ID - ref2 ER - TY - JOUR AU - Ma, C. X. AU - Bose, R. AU - Ellis, M. J. PY - 2016 DA - 2016// TI - Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast Cancer JO - Adv Exp Med Biol VL - 882 UR - https://doi.org/10.1007/978-3-319-22909-6_5 DO - 10.1007/978-3-319-22909-6_5 ID - Ma2016 ER - TY - JOUR AU - Miller, W. R. AU - Larionov, A. AU - Renshaw, L. AU - Anderson, T. J. AU - Walker, J. R. AU - Krause, A. PY - 2009 DA - 2009// TI - Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.16.8849 DO - 10.1200/JCO.2008.16.8849 ID - Miller2009 ER - TY - JOUR AU - Mello-Grand, M. AU - Singh, V. AU - Ghimenti, C. AU - Scatolini, M. AU - Regolo, L. AU - Grosso, E. PY - 2010 DA - 2010// TI - Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer JO - Breast Cancer Res Treat VL - 121 UR - https://doi.org/10.1007/s10549-010-0887-y DO - 10.1007/s10549-010-0887-y ID - Mello-Grand2010 ER - TY - JOUR AU - Harvell, D. M. AU - Spoelstra, N. S. AU - Singh, M. AU - McManaman, J. L. AU - Finlayson, C. AU - Phang, T. PY - 2008 DA - 2008// TI - Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance JO - Breast Cancer Res Treat VL - 112 UR - https://doi.org/10.1007/s10549-008-9897-4 DO - 10.1007/s10549-008-9897-4 ID - Harvell2008 ER - TY - JOUR AU - Knudsen, S. AU - Jensen, T. AU - Hansen, A. AU - Mazin, W. AU - Lindemann, J. AU - Kuter, I. PY - 2014 DA - 2014// TI - Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0087415 DO - 10.1371/journal.pone.0087415 ID - Knudsen2014 ER - TY - JOUR AU - Ueno, T. AU - Saji, S. AU - Sugimoto, M. AU - Masuda, N. AU - Kuroi, K. AU - Sato, N. PY - 2016 DA - 2016// TI - Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2270-9 DO - 10.1186/s12885-016-2270-9 ID - Ueno2016 ER - TY - JOUR AU - Miller, C. A. AU - Gindin, Y. AU - Lu, C. AU - Griffith, O. L. AU - Griffith, M. AU - Shen, D. PY - 2016 DA - 2016// TI - Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12498 DO - 10.1038/ncomms12498 ID - Miller2016 ER - TY - JOUR AU - Turnbull, A. K. AU - Arthur, L. M. AU - Renshaw, L. AU - Larionov, A. A. AU - Kay, C. AU - Dunbier, A. K. PY - 2015 DA - 2015// TI - Accurate prediction and validation of response to endocrine therapy in breast Cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.8963 DO - 10.1200/JCO.2014.57.8963 ID - Turnbull2015 ER - TY - JOUR AU - Lerebours, F. AU - Rivera, S. AU - Mouret-Reynier, M. A. AU - Alran, S. AU - Venat-Bouvet, L. AU - Kerbrat, P. PY - 2016 DA - 2016// TI - Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609) JO - Cancer VL - 122 UR - https://doi.org/10.1002/cncr.30143 DO - 10.1002/cncr.30143 ID - Lerebours2016 ER - TY - JOUR AU - Salgado, R. AU - Denkert, C. AU - Demaria, S. AU - Sirtaine, N. AU - Klauschen, F. AU - Pruneri, G. PY - 2015 DA - 2015// TI - The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014 JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdu450 DO - 10.1093/annonc/mdu450 ID - Salgado2015 ER - TY - JOUR AU - Kim, D. AU - Pertea, G. AU - Trapnell, C. AU - Pimentel, H. AU - Kelley, R. AU - Salzberg, S. L. PY - 2013 DA - 2013// TI - TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions JO - Genome Biol VL - 14 UR - https://doi.org/10.1186/gb-2013-14-4-r36 DO - 10.1186/gb-2013-14-4-r36 ID - Kim2013 ER - TY - JOUR AU - Trapnell, C. AU - Williams, B. A. AU - Pertea, G. AU - Mortazavi, A. AU - Kwan, G. AU - van Baren, M. J. PY - 2010 DA - 2010// TI - Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation JO - Nat Biotechnol VL - 28 UR - https://doi.org/10.1038/nbt.1621 DO - 10.1038/nbt.1621 ID - Trapnell2010 ER - TY - JOUR AU - Ritchie, M. E. AU - Phipson, B. AU - Wu, D. AU - Hu, Y. AU - Law, C. W. AU - Shi, W. PY - 2015 DA - 2015// TI - limma powers differential expression analyses for RNA-sequencing and microarray studies JO - Nucleic Acids Res VL - 43 UR - https://doi.org/10.1093/nar/gkv007 DO - 10.1093/nar/gkv007 ID - Ritchie2015 ER - TY - JOUR AU - Kramer, A. AU - Green, J. AU - Pollard, J. AU - Tugendreich, S. PY - 2014 DA - 2014// TI - Causal analysis approaches in ingenuity pathway analysis JO - Bioinformatics VL - 30 UR - https://doi.org/10.1093/bioinformatics/btt703 DO - 10.1093/bioinformatics/btt703 ID - Kramer2014 ER - TY - JOUR AU - Vacher, S. AU - Castagnet, P. AU - Chemlali, W. AU - Lallemand, F. AU - Meseure, D. AU - Pocard, M. PY - 2018 DA - 2018// TI - High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism JO - PLoS One VL - 13 UR - https://doi.org/10.1371/journal.pone.0190619 DO - 10.1371/journal.pone.0190619 ID - Vacher2018 ER - TY - JOUR AU - Decraene, C. AU - Silveira, A. B. AU - Bidard, F. C. AU - Vallee, A. AU - Michel, M. AU - Melaabi, S. PY - 2018 DA - 2018// TI - Multiple hotspot mutations scanning by single droplet digital PCR JO - Clin Chem VL - 64 UR - https://doi.org/10.1373/clinchem.2017.272518 DO - 10.1373/clinchem.2017.272518 ID - Decraene2018 ER - TY - JOUR PY - 2012 DA - 2012// TI - Comprehensive molecular portraits of human breast tumours JO - Nature VL - 490 UR - https://doi.org/10.1038/nature11412 DO - 10.1038/nature11412 ID - ref19 ER - TY - JOUR AU - Patani, N. AU - Dunbier, A. K. AU - Anderson, H. AU - Ghazoui, Z. AU - Ribas, R. AU - Anderson, E. PY - 2014 DA - 2014// TI - Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-1378 DO - 10.1158/1078-0432.CCR-13-1378 ID - Patani2014 ER - TY - JOUR AU - Spiegelberg, B. D. AU - Hamm, H. E. PY - 2007 DA - 2007// TI - Roles of G-protein-coupled receptor signaling in cancer biology and gene transcription JO - Curr Opin Gnet Dev VL - 17 UR - https://doi.org/10.1016/j.gde.2006.12.002 DO - 10.1016/j.gde.2006.12.002 ID - Spiegelberg2007 ER - TY - JOUR AU - Park, H. J. AU - Kim, M. K. AU - Choi, K. S. AU - Jeong, J. W. AU - Bae, S. K. AU - Kim, H. J. PY - 2016 DA - 2016// TI - Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells JO - Int J Oncol VL - 49 UR - https://doi.org/10.3892/ijo.2016.3590 DO - 10.3892/ijo.2016.3590 ID - Park2016 ER - TY - JOUR AU - Dalm, S. U. AU - Sieuwerts, A. M. AU - Look, M. P. AU - Melis, M. AU - van Deurzen, C. H. AU - Foekens, J. A. PY - 2015 DA - 2015// TI - Clinical relevance of targeting the gastrin-releasing peptide receptor, somatostatin receptor 2, or chemokine C-X-C motif receptor 4 in breast Cancer for imaging and therapy JO - J Nucl Med VL - 56 UR - https://doi.org/10.2967/jnumed.115.160739 DO - 10.2967/jnumed.115.160739 ID - Dalm2015 ER - TY - JOUR AU - Morgat, C. AU - MacGrogan, G. AU - Brouste, V. AU - Velasco, V. AU - Sevenet, N. AU - Bonnefoi, H. PY - 2017 DA - 2017// TI - Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors JO - J Nucl Med VL - 58 UR - https://doi.org/10.2967/jnumed.116.188011 DO - 10.2967/jnumed.116.188011 ID - Morgat2017 ER - TY - JOUR AU - Leithner, K. AU - Hirschmugl, B. AU - Li, Y. AU - Tang, B. AU - Papp, R. AU - Nagaraj, C. PY - 2016 DA - 2016// TI - TASK-1 regulates apoptosis and proliferation in a subset of non-small cell lung cancers JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0157453 DO - 10.1371/journal.pone.0157453 ID - Leithner2016 ER - TY - JOUR AU - Loi, S. AU - Michiels, S. AU - Salgado, R. AU - Sirtaine, N. AU - Jose, V. AU - Fumagalli, D. PY - 2014 DA - 2014// TI - Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu112 DO - 10.1093/annonc/mdu112 ID - Loi2014 ER - TY - JOUR AU - Adams, S. AU - Gray, R. J. AU - Demaria, S. AU - Goldstein, L. AU - Perez, E. A. AU - Shulman, L. N. PY - 2014 DA - 2014// TI - Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.55.0491 DO - 10.1200/JCO.2013.55.0491 ID - Adams2014 ER - TY - JOUR AU - Denkert, C. AU - von Minckwitz, G. AU - Brase, J. C. AU - Sinn, B. V. AU - Gade, S. AU - Kronenwett, R. PY - 2015 DA - 2015// TI - Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.1967 DO - 10.1200/JCO.2014.58.1967 ID - Denkert2015 ER - TY - JOUR AU - Loi, S. AU - Sirtaine, N. AU - Piette, F. AU - Salgado, R. AU - Viale, G. AU - Van Eenoo, F. PY - 2013 DA - 2013// TI - Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2011.41.0902 DO - 10.1200/JCO.2011.41.0902 ID - Loi2013 ER - TY - JOUR AU - Dieci, M. V. AU - Griguolo, G. AU - Miglietta, F. AU - Guarneri, V. PY - 2016 DA - 2016// TI - The immune system and hormone-receptor positive breast cancer: is it really a dead end? JO - Cancer Treat Rev VL - 46 UR - https://doi.org/10.1016/j.ctrv.2016.03.011 DO - 10.1016/j.ctrv.2016.03.011 ID - Dieci2016 ER - TY - JOUR AU - Dunbier, A. K. AU - Ghazoui, Z. AU - Anderson, H. AU - Salter, J. AU - Nerurkar, A. AU - Osin, P. PY - 2013 DA - 2013// TI - Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-1000 DO - 10.1158/1078-0432.CCR-12-1000 ID - Dunbier2013 ER - TY - JOUR AU - Blucher, C. AU - Stadler, S. C. PY - 2017 DA - 2017// TI - Obesity and breast cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast Cancer growth and progression JO - Front Endocrinol (Lausanne) VL - 8 UR - https://doi.org/10.3389/fendo.2017.00293 DO - 10.3389/fendo.2017.00293 ID - Blucher2017 ER - TY - JOUR AU - Rosen, E. D. AU - Sarraf, P. AU - Troy, A. E. AU - Bradwin, G. AU - Moore, K. AU - Milstone, D. S. PY - 1999 DA - 1999// TI - PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro JO - Mol Cell VL - 4 UR - https://doi.org/10.1016/S1097-2765(00)80211-7 DO - 10.1016/S1097-2765(00)80211-7 ID - Rosen1999 ER - TY - JOUR AU - Ellis, M. J. AU - Lin, L. AU - Crowder, R. AU - Tao, Y. AU - Hoog, J. AU - Snider, J. PY - 2010 DA - 2010// TI - Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer JO - Breast Cancer Res Treat VL - 119 UR - https://doi.org/10.1007/s10549-009-0575-y DO - 10.1007/s10549-009-0575-y ID - Ellis2010 ER - TY - JOUR AU - Baselga, J. AU - Semiglazov, V. AU - van Dam, P. AU - Manikhas, A. AU - Bellet, M. AU - Mayordomo, J. PY - 2009 DA - 2009// TI - Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.18.8391 DO - 10.1200/JCO.2008.18.8391 ID - Baselga2009 ER - TY - JOUR AU - Sanchez, C. G. AU - Ma, C. X. AU - Crowder, R. J. AU - Guintoli, T. AU - Phommaly, C. AU - Gao, F. PY - 2011 DA - 2011// TI - Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer JO - Breast Cancer Res VL - 13 UR - https://doi.org/10.1186/bcr2833 DO - 10.1186/bcr2833 ID - Sanchez2011 ER - TY - JOUR AU - Araki, K. AU - Miyoshi, Y. PY - 2018 DA - 2018// TI - Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer JO - Breast Cancer. 2017 VL - 25 ID - Araki2018 ER - TY - JOUR AU - Keegan, N. M. AU - Gleeson, J. P. AU - Hennessy, B. T. AU - Morris, P. G. PY - 2018 DA - 2018// TI - PI3K inhibition to overcome endocrine resistance in breast cancer JO - Expert Opin Investig Drugs VL - 27 UR - https://doi.org/10.1080/13543784.2018.1417384 DO - 10.1080/13543784.2018.1417384 ID - Keegan2018 ER - TY - JOUR AU - Olivier, M. AU - Langerod, A. AU - Carrieri, P. AU - Bergh, J. AU - Klaar, S. AU - Eyfjord, J. PY - 2006 DA - 2006// TI - The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-1029 DO - 10.1158/1078-0432.CCR-05-1029 ID - Olivier2006 ER - TY - JOUR AU - Gyorffy, B. AU - Bottai, G. AU - Lehmann-Che, J. AU - Keri, G. AU - Orfi, L. AU - Iwamoto, T. PY - 2014 DA - 2014// TI - TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers JO - Mol Oncol VL - 8 UR - https://doi.org/10.1016/j.molonc.2013.12.018 DO - 10.1016/j.molonc.2013.12.018 ID - Gyorffy2014 ER - TY - JOUR AU - Berns, E. M. AU - Foekens, J. A. AU - Vossen, R. AU - Look, M. P. AU - Devilee, P. AU - Henzen-Logmans, S. C. PY - 2000 DA - 2000// TI - Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer JO - Cancer Res VL - 60 ID - Berns2000 ER - TY - JOUR AU - Karnik, P. S. AU - Kulkarni, S. AU - Liu, X. P. AU - Budd, G. T. AU - Bukowski, R. M. PY - 1994 DA - 1994// TI - Estrogen receptor mutations in tamoxifen-resistant breast cancer JO - Cancer Res VL - 54 ID - Karnik1994 ER - TY - JOUR AU - Roodi, N. AU - Bailey, L. R. AU - Kao, W. Y. AU - Verrier, C. S. AU - Yee, C. J. AU - Dupont, W. D. PY - 1995 DA - 1995// TI - Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer JO - J Natl Cancer Inst VL - 87 UR - https://doi.org/10.1093/jnci/87.6.446 DO - 10.1093/jnci/87.6.446 ID - Roodi1995 ER - TY - JOUR AU - Cerami, E. AU - Gao, J. AU - Dogrusoz, U. AU - Gross, B. E. AU - Sumer, S. O. AU - Aksoy, B. A. PY - 2012 DA - 2012// TI - The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0095 DO - 10.1158/2159-8290.CD-12-0095 ID - Cerami2012 ER - TY - JOUR AU - Jeselsohn, R. AU - Buchwalter, G. AU - De Angelis, C. AU - Brown, M. AU - Schiff, R. PY - 2015 DA - 2015// TI - ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer JO - Nat Rev Clin Oncol VL - 12 UR - https://doi.org/10.1038/nrclinonc.2015.117 DO - 10.1038/nrclinonc.2015.117 ID - Jeselsohn2015 ER - TY - JOUR AU - Huggett, J. F. AU - Cowen, S. AU - Foy, C. A. PY - 2015 DA - 2015// TI - Considerations for digital PCR as an accurate molecular diagnostic tool JO - Clin Chem VL - 61 UR - https://doi.org/10.1373/clinchem.2014.221366 DO - 10.1373/clinchem.2014.221366 ID - Huggett2015 ER -